Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | HMOX2 | P30519 | 1/20 | 1.00 |
| ▸ | CRYZ | Q08257 | 1/20 | 1.00 |
| ▸ | VAT1 | Q99536 | 1/20 | 1.00 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637284 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29373530 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658077 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128690 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765662 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647182 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29766035 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646915 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18842314 | 0.91 | KRAS (0.83) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL21471922 | 0.90 | KRAS (0.82) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226775-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025226775-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4247787-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-116745264-A | Methods and compositions for KRAS modification | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4143237-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | Genentech, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 235/4885HMOX2 4490/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.